<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966887</url>
  </required_header>
  <id_info>
    <org_study_id>P081252</org_study_id>
    <nct_id>NCT01966887</nct_id>
  </id_info>
  <brief_title>AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure</brief_title>
  <acronym>AGENT-HF</acronym>
  <official_title>Phase 2 Study of SERCA2a Gene Transfer in Patients With Severe Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celladon Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of intracoronary SERCA2a Gene transfer
      on cardiac volumes and function using multimodality cardiac imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of gene transfer of SERCA2a is to improve systolic and diastolic function of the
      failing ventricle. Studies show that reduction of SERCA2a in failing ventricle is a key
      factor in depression of contraction, and that restoration of SERCA2a levels can improve left
      ventricular function and remodeling. The aim of the study is to investigate the effect of an
      adeno-associated viral vector expressing the sarcoplasmic reticulum calcium ATPase (SERCA2a),
      driven by the CMV promoter (AAV1-CMV-SERCA2a), on the ventricular remodeling of patients with
      severe heart failure using multimodality cardiac imaging. This is a Phase 2 monocenter double
      blind randomized placebo-controled, parallel study. The study will enroll 44 symptomatic
      heart failure patients with NYHA IIIb/IV, with left-ventricular ejection fraction of 35% or
      less receiving an optimal standard medical therapy. The absence of neutralizing antibodies
      against AAV1 will be primarily checked. Seronegative patients will be randomized to receive
      either 1x10e13 AAV1-CMV-Serca2a or a placebo as a single intracoronary infusion. Evolution
      during the next 6 months of the left ventricular end-systolic volume (measured with a
      256-slices CT-scan before injection and 6 months later) will be the primary endpoint.
      Secondary endpoints will include changes in the LVEF, diastolic volumes, VO2max,
      Echocardiographic remodeling, BNP, cardiac hemodynamics and biological safety profile.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular end-systolic volume measured by CT-Scan</measure>
    <time_frame>at 6 months</time_frame>
    <description>left ventricular end-systolic volume measured by CT-Scan / changes from baseline to 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CT-scan other measurments: left ventricular end-diastolic volume</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>CT-scan other measurments: left ventricular end-diastolic volume / changes from baseline to 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac volumes and function</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Cardiac volumes and function / changes from baseline to 6 months &amp; 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac hemodynamic parameters</measure>
    <time_frame>at 6 months</time_frame>
    <description>Cardiac hemodynamic parameters; changes from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>VO2 max; changes from baseline to 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function assessed by echocardiography</measure>
    <time_frame>at 6 and12 months</time_frame>
    <description>Changes from baseline to 6 and12 months in:Echocardiographic assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Kansas city score)</measure>
    <time_frame>at 3,6,9,12 months</time_frame>
    <description>Changes from baseline to 3,6,9,12 months in:Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-ProBNP</measure>
    <time_frame>at 6 and12 months</time_frame>
    <description>Changes from baseline to 6 and12 months in:NT-ProBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cardiovascular event</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Time to cardiovascular event (all-cause death, heart transplant, LVAD implantation) - administration to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalized patients for worsening heart failure</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac volumes assessed by echocardiography</measure>
    <time_frame>at 6 and12 months</time_frame>
    <description>Changes from baseline to 6 and12 months in:Echocardiographic assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT-scan other measurments: left ventricular end-systolic volume</measure>
    <time_frame>12 months</time_frame>
    <description>CT-scan other measurments: left ventricular end-systolic volume / changes from baseline to 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Heart Failure Congestive</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>MYDICAR-single intracoronary infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genetic / AAV1 Serca2a (MYDICAR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; single intracoronary infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>MYDICAR-single intracoronary infusion</intervention_name>
    <description>AAV1/Serca2a</description>
    <arm_group_label>MYDICAR-single intracoronary infusion</arm_group_label>
    <other_name>1x10e13 DRP; single intracoronary infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Placebo; single intracoronary infusion</intervention_name>
    <description>single intracoronary infusion</description>
    <arm_group_label>Placebo; single intracoronary infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NYHA class III / IV severe heart failure ≥ 3 months

          -  Ischemic or non-ischemic origin

          -  Left ventricular ejection fraction ≤35%

          -  Patients must be receiving optimal (maximum tolerated doses) medical treatment
             (diuretics, renin-angiotensin-aldosterone system blockers, beta blockers, ±Ivabradine)
             for at least 1 month (with the exception of diuretic dose titration) and must be
             stable.

          -  No decompensated congestive heart failure within the past month

          -  With or without an ICD if the ICD was implanted over 3 months ago, with or without
             biventricular pacing if the RCT was implanted over 6 months ago

          -  All women of childbearing potential must have a negative urine pregnancy test prior to
             administration of investigational medicinal product

          -  Patient must have given written informed consent to participate in this study

        Exclusion Criteria:

          -  &lt;18 or &gt;80 years old

          -  AAV1 seropositivity (titer &lt;1:2) in the last 3 months

          -  Atrial fibrillation in the absence of permanent ventricular pacing

          -  Coronary revascularization or heart surgery or pacemaker implantation &lt; 3 months

          -  Ischemic heart disease without at least one coronary artery with a TIMI-3 flow

          -  Restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy, pericardial
             disease, cardiac amyloidosis

          -  Heart transplant, an already implanted or needing to urgently implant external
             ventricular assist device

          -  Myocardial infarction (STEMI or NSTEMI) &lt; 3 months

          -  Treatment with intravenous positive inotropic agents or diuretics in the past 28 days

          -  Pregnant or nursing patient

          -  Female patient of childbearing age with no effective means of contraception

          -  Severe renal failure defined by a creatinine clearance of &lt; 30 mL/min (last bloodwork
             done less than 6 months)

          -  Liver failure, chronic liver disease or laboratory tests &gt; 3 x N (AST, ALT, ALP))(last
             bloodwork done less than 6 months)

          -  Thrombocytopenia (&lt;50,000/mm3

          -  Patient treated with immunosuppressants, has an immunodeficiency or whose neutrophil
             count &lt; 1000 mm3

          -  Recent sepsis (&lt; 3 months)

          -  Active neoplasia or treated &lt; 5 years

          -  No medical insurance

          -  Patient is enrolled in another randomized study

          -  Patient does not understand the protocol procedures sponsor suspects poor compliance
             with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Sébastien HULOT, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, Logeart D, Gandjbakhch E, Bernard C, Hatem SN, Isnard R, Cluzel P, Le Feuvre C, Leprince P, Hammoudi N, Lemoine FM, Klatzmann D, Vicaut E, Komajda M, Montalescot G, Lompré AM, Hajjar RJ; AGENT-HF Investigators. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial. Eur J Heart Fail. 2017 Nov;19(11):1534-1541. doi: 10.1002/ejhf.826. Epub 2017 Apr 10.</citation>
    <PMID>28393439</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Serca2a</keyword>
  <keyword>Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

